• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination Therapy With Olaparib Plus Lenvatinib in a Patient With -Mutated, Radioiodine-Refractory, Metastatic Papillary Thyroid Cancer: A Case Report.

作者信息

Young Zachary, Tasoulas Jason, Fajardo Marco, Gwynn Morgan, Morris Jacqueline, Johnson Steven M, Sheth Siddharth

机构信息

Masters of Biomedical Sciences Program, Duke University School of Medicine, Durham, NC.

Department of Otolaryngology/Head and Neck Surgery, University of North Carolina School of Medicine, Chapel Hill, NC.

出版信息

JCO Precis Oncol. 2025 Jul;9:e2400802. doi: 10.1200/PO-24-00802. Epub 2025 Jul 23.

DOI:10.1200/PO-24-00802
PMID:40700671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12309517/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1dc/12309517/da2ee5f21a54/po-9-e2400802-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1dc/12309517/e80301e918fb/po-9-e2400802-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1dc/12309517/1e27a3fa091f/po-9-e2400802-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1dc/12309517/da2ee5f21a54/po-9-e2400802-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1dc/12309517/e80301e918fb/po-9-e2400802-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1dc/12309517/1e27a3fa091f/po-9-e2400802-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1dc/12309517/da2ee5f21a54/po-9-e2400802-g003.jpg

相似文献

1
Combination Therapy With Olaparib Plus Lenvatinib in a Patient With -Mutated, Radioiodine-Refractory, Metastatic Papillary Thyroid Cancer: A Case Report.奥拉帕利联合乐伐替尼治疗BRAF V600E突变、放射性碘难治性转移性甲状腺乳头状癌1例报告
JCO Precis Oncol. 2025 Jul;9:e2400802. doi: 10.1200/PO-24-00802. Epub 2025 Jul 23.
2
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.卡博替尼对比安慰剂可提高碘难治性分化型甲状腺癌患者的无进展生存期，与既往是否接受血管内皮生长因子受体靶向治疗及肿瘤组织学类型无关：COS-MIC-311 研究的亚组分析。
Thyroid. 2024 Mar;34(3):347-359. doi: 10.1089/thy.2023.0463. Epub 2024 Jan 23.
3
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation.奥拉帕利单药治疗或与阿比特龙联合用于治疗转移性去势抵抗性前列腺癌（mCRPC）且存在BRCA突变的患者。
Target Oncol. 2025 May 21. doi: 10.1007/s11523-025-01146-4.
4
Therapeutic Efficacy of a Very Low/Low Dose of Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer: A Real-World Series from a Single Center.极低/低剂量乐伐替尼治疗晚期放射性碘难治性甲状腺癌的疗效：来自单一中心的真实世界系列研究
Cancers (Basel). 2025 Jul 17;17(14):2372. doi: 10.3390/cancers17142372.
5
Real-world lenvatinib use in metastatic thyroid cancer: early dose intensity and side effect profile in an Australian centre.乐伐替尼在转移性甲状腺癌中的真实世界应用：澳大利亚一家中心的早期剂量强度和副作用情况
Endocr Oncol. 2025 Jun 19;5(1):e240062. doi: 10.1530/EO-24-0062. eCollection 2025 Jan.
6
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study.与多原发性肿瘤高风险相关的BRCA功能域及与奥拉帕利相关的结构域敏感性：普罗米修斯研究
ESMO Open. 2025 Feb;10(2):104076. doi: 10.1016/j.esmoop.2024.104076. Epub 2025 Jan 22.
7
A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic -Mutated Thyroid Cancer in Japan.在日本转移性突变型甲状腺癌患者中联合使用恩考芬尼和比尼替尼的 2 期研究。
Thyroid. 2024 Apr;34(4):467-476. doi: 10.1089/thy.2023.0547. Epub 2024 Mar 14.
8
Long-Term Clinical Outcomes of Patients with Differentiated Thyroid Cancer Treated with Lenvatinib: Results from Real-World Practice in Japan.使用乐伐替尼治疗的分化型甲状腺癌患者的长期临床结局：来自日本真实临床实践的结果
Thyroid. 2025 Jul;35(7):781-788. doi: 10.1089/thy.2025.0040. Epub 2025 Jun 9.
9
Predictors of response to lenvatinib in advanced differentiated thyroid cancer: focus on the CONUT score.晚期分化型甲状腺癌中乐伐替尼治疗反应的预测因素：聚焦CONUT评分
Endocrine. 2025 Apr 11. doi: 10.1007/s12020-025-04228-5.
10
Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.儿童甲状腺乳头状癌患者对乐伐替尼的反应。
Thyroid. 2018 Nov;28(11):1450-1454. doi: 10.1089/thy.2018.0064. Epub 2018 Oct 16.

本文引用的文献

1
Cardiac Conduction System as an OAR in Radiation Therapy: Doses to SA/AV Nodes and Their Reduction.心脏传导系统作为放射治疗中的一个危及器官：窦房结/房室结的剂量及其降低
Int J Part Ther. 2024 Sep 26;14:100631. doi: 10.1016/j.ijpt.2024.100631. eCollection 2024 Dec.
2
Thyroid Cancer: A Review.甲状腺癌：综述。
JAMA. 2024 Feb 6;331(5):425-435. doi: 10.1001/jama.2023.26348.
3
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.卡博替尼治疗经碘治疗后复发的分化型甲状腺癌：III 期 COSMIC-311 试验的更新结果。
Cancer. 2022 Dec 15;128(24):4203-4212. doi: 10.1002/cncr.34493. Epub 2022 Oct 19.
4
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.甲状腺癌临床实践指南（NCCN 指南）2022 年第 2 版。
J Natl Compr Canc Netw. 2022 Aug;20(8):925-951. doi: 10.6004/jnccn.2022.0040.
5
Dabrafenib Versus Dabrafenib + Trametinib in -Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.达拉非尼对比达拉非尼联合曲美替尼治疗放射性碘难治性分化型甲状腺癌（BRAF V600E 突变阳性）：一项随机、开放标签、多中心、2 期临床试验的结果。
Thyroid. 2022 Oct;32(10):1184-1192. doi: 10.1089/thy.2022.0115. Epub 2022 Jul 5.
6
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.奥拉帕利联合或不联合 Cediranib 与铂类化疗治疗铂类敏感复发性卵巢癌（NRG-GY004）：一项随机、开放标签、III 期临床试验。
J Clin Oncol. 2022 Jul 1;40(19):2138-2147. doi: 10.1200/JCO.21.02011. Epub 2022 Mar 15.
7
A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.乐伐替尼 18mg 与 24mg 治疗碘难治性分化型甲状腺癌的随机研究
J Clin Endocrinol Metab. 2022 Feb 17;107(3):776-787. doi: 10.1210/clinem/dgab731.
8
Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma - A Real-World Experience.低剂量乐伐替尼治疗放射性碘难治性分化型甲状腺癌患者——一项真实世界经验
Cancer Manag Res. 2021 Sep 14;13:7139-7148. doi: 10.2147/CMAR.S326255. eCollection 2021.
9
Significance of RAS Mutations in Thyroid Benign Nodules and Non-Medullary Thyroid Cancer.RAS突变在甲状腺良性结节和非髓样甲状腺癌中的意义
Cancers (Basel). 2021 Jul 27;13(15):3785. doi: 10.3390/cancers13153785.
10
Mechanisms of DNA damage, repair, and mutagenesis.DNA损伤、修复及诱变机制
Environ Mol Mutagen. 2017 Jun;58(5):235-263. doi: 10.1002/em.22087. Epub 2017 May 9.